Table 5.
Risk of disease enhancement in participants with COVID-19 in SARS-CoV-2-naïve participants.
|
SCB-2019 N = 6336 |
Placebo N = 6216 |
|
|---|---|---|
| Participants with RT-PCR-confirmed COVID-19 of any severity from 14 days after the second dose | 256 | 486 |
| Participants with RT-PCR-confirmed severe COVID-19 from 14 days after the second dose | 0 | 20 |
| Ratio of severe COVID-19 to COVID-19 of any severity (%) | 0.0 | 4.1 |
Abbreviations: RT-PCR, reverse transcriptase-polymerase chain reaction; COVID-19, coronavirus disease.
This analysis was performed in participants who had no evidence of prior SARS-CoV-2 infection at baseline (per-protocol set for efficacy).